Symptoms of mild heart failure (NYHA II)
Not recommended
Hawthorn is a herbal product with HMPC traditional use for mild chronic heart failure symptoms (NYHA I–II) in patients in whom severe pathology has been excluded. The Cochrane 2008 review reported moderate improvement in exercise tolerance and dyspnoea. The large SPICE trial (Holubarsch 2008, n = 2681, NYHA II–III) gave the headline result: WS 1442 does not reduce cardiovascular mortality on top of standard therapy. The HF 2021 guideline does not include hawthorn in the chronic heart failure treatment algorithm. Hawthorn does not replace ACE inhibitors, beta-blockers, mineralocorticoid antagonists or SGLT2 inhibitors. If hawthorn was offered as a substitute for standard therapy, consider seeking a second opinion from a cardiologist.
Sources
- EMA HMPC: Community herbal monograph on Crataegus spp., folium cum flore (2016)
- Cochrane: Hawthorn extract for treating chronic heart failure (2008)
- Eur J Heart Fail: The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial (2008)
- ESC: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021)